Valuation : Rein Therapeutics Inc.

Market Cap 76.7M 66M 62.1M 56.73M 106M 7.24B 106M 734M 285M 3.72B 288M 282M 11.97B P/E 2026 *
-1.93x
P/E 2027 * -1.91x
Enterprise Value 76.7M 66M 62.1M 56.73M 106M 7.24B 106M 734M 285M 3.72B 288M 282M 11.97B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.98%
Yield 2026 *
-
Yield 2027 * -
1 day+5.39%
1 week+16.66%
Current month+18.56%
1 month+24.45%
3 months-5.73%
6 months-25.29%
Current year-23.35%
1 week 0.73
Extreme 0.7293
0.92
1 month 0.73
Extreme 0.7293
0.92
Current year 0.69
Extreme 0.694
2.1
1 year 0.69
Extreme 0.694
2.18
3 years 0.69
Extreme 0.694
7.42
5 years 0.69
Extreme 0.694
25.4
10 years 0.69
Extreme 0.694
309.6
Manager TitleAgeSince
Chief Executive Officer 60 2024-03-10
Director of Finance/CFO 64 2024-05-15
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 70 2013-05-31
Chairman 71 2023-10-30
Director/Board Member 60 2024-03-10
Date Insider Type Main position Quantity % Market Cap. Importance
5/27/26 Buy

Chairman

4,500 0.0058%
5/8/26 Free

Chief Executive Officer

-150,000 0.1922%
11/14/25
Voss Capital LP
BuyCompany 104,183 0.4424%
Change 5-day change 1-year change 3-year change Capi.($)
+5.39%+16.66%-33.15%-46.44% 76.7M
-1.79%-2.27%+43.23%+88.96% 67.98B
-2.06%-0.18%+39.67%+86.44% 64.94B
-0.31%+6.54%-12.96%+378.92% 27.58B
+0.86%+1.65%-7.74%-14.95% 26.06B
-3.00%-2.90%+33.13%+12.54% 25.74B
-1.46%+0.42%+23.61%-18.61% 20.09B
-2.96%-15.21%+216.20%+368.10% 17.16B
-1.49%-4.88%-6.60%+531.89% 14.92B
-0.20%+8.37%+55.78%+164.98% 14.62B
Average -0.70%+1.90%+35.12%+155.18% 27.92B
Weighted average by Cap. -1.52%+0.18%+38.35%+137.30%

Financials

2026 *2027 *
Net sales - -
Net income -29.15M -25.09M -23.6M -21.56M -40.33M -2.75B -40.44M -279M -108M -1.41B -109M -107M -4.55B -37.01M -31.85M -29.97M -27.38M -51.21M -3.49B -51.35M -354M -137M -1.79B -139M -136M -5.78B
Net Debt - -
Logo Rein Therapeutics Inc.
Rein Therapeutics, Inc., formerly Aileron Therapeutics, Inc., is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. The Company's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).
Employees
10
Date Price Change Volume
26-09-04 US$0.8891 +5.39% 986,045
26-09-03 US$0.8436 +8.88% 568,107
26-09-02 US$0.7748 +2.94% 489,076
26-09-01 US$0.7527 +0.37% 344,262
26-08-31 US$0.7499 -1.60% 546,084
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.8891USD
Average target price
6.000USD
Spread / Average Target
+574.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RNTX Stock